Sirt1 activated mitochondrial biogenesis, and together with pAMPK inhibited PPARγ/SCREBP-1c induced FAS activity and TG levels to alleviate the NAFLD (Figure 9). This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.